Vinod Chauhan, MD
Cardiovascular Disease · South Bend, INNPI 1831196641
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Abbott at 55.6% of the total. Reporting peaked in 2022 at $1,722 and has fallen 95.1% since, to $84 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 45 payments — averaging $73.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$1K
- Novartis$64
- Covidien LP$46
- Boston Scientific$27
- Shockwave Medical, Inc$22
- plus $37 from 2 others
What the payments were for
- Travel & lodging$1,89157%
- Food & beverage$1,41543%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 19 | $1,840 |
| Medtronic | 17 | $1,271 |
| Novartis | 4 | $64 |
| Covidien LP | 1 | $46 |
| Boston Scientific | 1 | $27 |
| Shockwave Medical, Inc | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Elutia, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$1,320
How this compares
$3,307 in reported general payments places this provider in the 50th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 419 | $514,157 |
| XareltoRivaroxaban | 105 | $116,067 |
| Dofetilide | 273 | $41,293 |
| Flecainide Acetate | 350 | $17,011 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $4,684 |
| Amiodarone Hcl | 47 | $3,456 |
| Propafenone Hcl | 28 | $3,099 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 44 | $1,959 |
| Mexiletine Hcl | 18 | $1,653 |
| SotalolSotalol Hcl | 65 | $1,523 |
| Metoprolol Succinate | 118 | $1,351 |
| Metoprolol Tartrate | 129 | $1,018 |
| Potassium Chloride | 13 | $412 |
| Diltiazem Hcl | 16 | $398 |
| Carvedilol | 20 | $177 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in South Bend
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.